Le Registre des lobbyistes
GlaxoSmithKline Inc.
Objets | Détails | Catégories |
---|---|---|
Santé, Recherche et développement
|
Antimicrobial Resistance (AMR) - Identification of the need for a multi-sectoral stakeholder working group to pursue joint goals under a Pan-Canadian AMR strategy and to strengthen Canada's end-to-end research capacity in AMR.
|
Politique ou Programme
|
Développement économique, Santé, Commerce intérieur, Recherche et développement
|
Engage government officials regarding domestic manufacturing of seasonal and pandemic flu vaccine.
|
Politique ou Programme
|
Santé
|
Engage the government regarding the need for clear and efficient procurement processes for COVID-19 medical countermeasures, including COVID-19 therapeutics, to ensure access for Canadians.
|
Politique ou Programme
|
Santé, Vie privée et Accès à l'information
|
Engaging Health Canada on the Self-Care Products Initiative as it pertains to plain language labelling and a risk-based approach to regulatory oversight for non prescription drugs.
|
Règlement
|
Santé, Commerce intérieur, Recherche et développement
|
Ensure the National Advisory Committee on Immunization has sufficient resources to undertake timely reviews of new vaccines that are made available to the Canadian marketplace.
|
Politique ou Programme
|
Santé
|
Input on the work of the Advisory Committee on the Implementation of National Pharmacare, specifically as it relates to access to medicines.
|
Politique ou Programme
|
Santé, Vie privée et Accès à l'information, Recherche et développement, Sciences et technologies
|
Participation in consultations regarding the Digital Charter and the federal government's plans to overhaul Canada's privacy regime, to enable the use of anonymized health data for new medication research and development.
|
Proposition législative, Projet de loi ou résolution
|
Santé, Commerce international, Justice et application des lois
|
Raise awareness regarding the potential risks to drug and vaccine supply for Canadian patients arising from new U.S. state-level reimportation legislation.
|
Proposition législative, Projet de loi ou résolution
|
Santé, Propriété intellectuelle, Recherche et développement
|
Reforms to the Patented Medicines Review Board (PMPRB), whose guidelines seek to ensure a balance between the prices set by manufacturers for patented medicines sold in Canada and the maintenance of an attractive environment for pharmaceutical research and development. Specifically with regard to ensuring that any actions and proposed changes by the PMPRB do not negatively impact access to patented medicines in Canada.
|
Règlement
|
Développement économique, Santé, Recherche et développement
|
Renewal of national vaccine strategy to close gaps in vaccination coverage for Canadians, especially among seniors.
|
Politique ou Programme
|
Développement économique, Santé, Commerce intérieur, Justice et application des lois
|
Sharing information with government and Members of Parliament on different models for national pharmacare, specifically as it relates to access to medicines.
|
Politique ou Programme
|
Santé
|
The Government of Ontario has passed legislation requiring the public disclosure of payments made to Health Care Providers and Health Care Organizations by the broader health care industry, including pharmaceutical companies, generic manufacturers, and medical device companies. GlaxoSmithKline seeks to advocate for a national approach to disclosure through either the support of similar provincial initiatives, coordinated action through the Federal / Provincial and Territorial meetings of the Ministers of Health, and / or the establishment of national requirements.
|
Politique ou Programme
|